滤泡性淋巴瘤-话题@MedSci

#滤泡性淋巴瘤#

69篇内容 | 5166人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278777, encodeId=10d012e877710, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat：Voxtalisib（XL765）用于滤泡性淋巴瘤患者可获得良好的治疗效果, objectType=article, longId=132542, objectId=4f8e13254254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8e13254254, replyNumber=0, likeNumber=94, createdTime=2018-03-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8e13254254, moduleTitle=Lancet haemat：Voxtalisib（XL765）用于滤泡性淋巴瘤患者可获得良好的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f8e13254254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278776, encodeId=973212e8776ba, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=CLIN CANCER RES：滤泡性淋巴瘤中表达TIGIT的T细胞增多, objectType=article, longId=130882, objectId=c3ec130882e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3ec130882e6, replyNumber=0, likeNumber=78, createdTime=2018-03-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3ec130882e6, moduleTitle=CLIN CANCER RES：滤泡性淋巴瘤中表达TIGIT的T细胞增多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3ec130882e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278775, encodeId=f2e012e877577, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？, objectType=article, longId=130821, objectId=fe7113082182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7113082182, replyNumber=0, likeNumber=55, createdTime=2018-03-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7113082182, moduleTitle=Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7113082182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278774, encodeId=63ea12e87748f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, objectType=article, longId=127695, objectId=d57d12e6952c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d57d12e6952c, replyNumber=0, likeNumber=83, createdTime=2018-01-27, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d57d12e6952c, moduleTitle=Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d57d12e6952c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278773, encodeId=ca7c12e8773ff, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, objectType=article, longId=120773, objectId=59cb120e7346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59cb120e7346, replyNumber=0, likeNumber=93, createdTime=2017-11-22, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59cb120e7346, moduleTitle=Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59cb120e7346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278772, encodeId=5dcc12e877258, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：依鲁替尼治疗复发性或难治性滤泡性淋巴瘤的效果。, objectType=article, longId=118210, objectId=31021182100f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31021182100f, replyNumber=0, likeNumber=77, createdTime=2017-11-01, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31021182100f, moduleTitle=Blood：依鲁替尼治疗复发性或难治性滤泡性淋巴瘤的效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31021182100f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278771, encodeId=910812e877108, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=NEJM：Obinutuzumab治疗滤泡性淋巴瘤的效果如何？, objectType=article, longId=115357, objectId=191e11535e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=191e11535e34, replyNumber=0, likeNumber=101, createdTime=2017-10-09, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=191e11535e34, moduleTitle=NEJM：Obinutuzumab治疗滤泡性淋巴瘤的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=191e11535e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278770, encodeId=e20b12e877032, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=治疗复发性滤泡性淋巴瘤的新疗法, objectType=article, longId=113010, objectId=afe9113010c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe9113010c9, replyNumber=0, likeNumber=77, createdTime=2017-09-18, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe9113010c9, moduleTitle=治疗复发性滤泡性淋巴瘤的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe9113010c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278769, encodeId=7fb312e876961, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=BJH:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, objectType=article, longId=108312, objectId=cde91083121f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cde91083121f, replyNumber=0, likeNumber=111, createdTime=2017-08-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cde91083121f, moduleTitle=BJH:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cde91083121f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278768, encodeId=f11d12e8768c4, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Brit J Haematol:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, objectType=article, longId=108284, objectId=1f1c10828430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1c10828430, replyNumber=0, likeNumber=82, createdTime=2017-08-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1c10828430, moduleTitle=Brit J Haematol:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1c10828430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278767, encodeId=19d512e87679f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉, objectType=article, longId=105799, objectId=110d105e99fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=110d105e99fc, replyNumber=0, likeNumber=71, createdTime=2017-07-19, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=110d105e99fc, moduleTitle=Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=110d105e99fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278766, encodeId=2a1012e87669a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？, objectType=article, longId=100766, objectId=a2e7100e6654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e7100e6654, replyNumber=0, likeNumber=102, createdTime=2017-06-07, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e7100e6654, moduleTitle=Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e7100e6654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278765, encodeId=48f512e876571, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=PLoS Med：科学家深入剖析滤泡性淋巴瘤的发病机理, objectType=article, longId=84448, objectId=5abd8444835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5abd8444835, replyNumber=0, likeNumber=78, createdTime=2016-12-17, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5abd8444835, moduleTitle=PLoS Med：科学家深入剖析滤泡性淋巴瘤的发病机理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5abd8444835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278764, encodeId=024e12e876409, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Cell：CAR-T细胞免疫治疗有望攻克滤泡性淋巴瘤, objectType=article, longId=79404, objectId=3433e9404ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3433e9404ae, replyNumber=0, likeNumber=98, createdTime=2016-10-08, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3433e9404ae, moduleTitle=Cell：CAR-T细胞免疫治疗有望攻克滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3433e9404ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278763, encodeId=a7e512e87632e, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=2016ESMO临床诊疗指南——新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访发布, objectType=article, longId=78484, objectId=c96ee84848f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c96ee84848f, replyNumber=0, likeNumber=92, createdTime=2016-09-28, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c96ee84848f, moduleTitle=2016ESMO临床诊疗指南——新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c96ee84848f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278762, encodeId=fb5a12e8762be, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=BMJ：罕见滤泡性淋巴瘤侵犯皮肤病例报道, objectType=article, longId=58480, objectId=eedf58480a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eedf58480a9, replyNumber=0, likeNumber=86, createdTime=2015-11-09, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eedf58480a9, moduleTitle=BMJ：罕见滤泡性淋巴瘤侵犯皮肤病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eedf58480a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278761, encodeId=5fdf12e876162, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加, objectType=article, longId=58165, objectId=68165816523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68165816523, replyNumber=0, likeNumber=75, createdTime=2015-11-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68165816523, moduleTitle=J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68165816523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278760, encodeId=b21512e8760c7, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=JCO：血清中高维生素D水平可能改善滤泡性淋巴瘤的预后, objectType=article, longId=48937, objectId=1a604893e17, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a604893e17, replyNumber=0, likeNumber=81, createdTime=2015-04-04, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a604893e17, moduleTitle=JCO：血清中高维生素D水平可能改善滤泡性淋巴瘤的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a604893e17)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

滤泡性淋巴瘤

2020-05-29

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet haemat：Voxtalisib（XL765）用于滤泡性淋巴瘤患者可获得良好的治疗效果

2018-03-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

CLIN CANCER RES：滤泡性淋巴瘤中表达TIGIT的T细胞增多

2018-03-01

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？

2018-03-01

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet haemat：R-CHOP、放疗、利妥昔单抗维持的序贯疗法治疗晚期滤泡性淋巴瘤的效果和安全性

2018-01-27

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：FOXP1表达可作为预测利妥昔单抗治疗滤泡性淋巴瘤预后的标志物。

2017-11-22

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：依鲁替尼治疗复发性或难治性滤泡性淋巴瘤的效果。

2017-11-01

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

NEJM：Obinutuzumab治疗滤泡性淋巴瘤的效果如何？

2017-10-09

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

治疗复发性滤泡性淋巴瘤的新疗法

2017-09-18

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

BJH:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？

2017-08-11

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Brit J Haematol:滤泡性淋巴瘤临床试验评效标准是否可取消骨髓活检？

2017-08-11

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet Haematol：利妥昔单抗一线治疗滤泡性淋巴瘤：皮下vs静脉

2017-07-19

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Am J Hematol：BCL2突变是否导致利妥昔单抗治疗的滤泡性淋巴瘤患者预后不良？

2017-06-07

柳叶一刀 (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

PLoS Med：科学家深入剖析滤泡性淋巴瘤的发病机理

2016-12-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Cell：CAR-T细胞免疫治疗有望攻克滤泡性淋巴瘤

2016-10-08

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

2016ESMO临床诊疗指南——新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访发布

2016-09-28

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

BMJ：罕见滤泡性淋巴瘤侵犯皮肤病例报道

2015-11-09

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加

2015-11-03

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

JCO：血清中高维生素D水平可能改善滤泡性淋巴瘤的预后

2015-04-04

科室
- - 订阅+
  - 更多科室
工具
服务